

R E M A R K S

The Examiner has restricted the claims into 3 different groups, which include the following: Group I (Claims 1-32 and 37-80) directed toward methods of amplifying and generating multiple copies of a target nucleic acid; Group II (Claims 33-34 and 82-83) directed toward methods for producing a microarray; and Group III (Claims 35-36) directed towards compositions and kits. Applicants hereby elect Group I without traverse. It is noted that all of the pending claims (1-83) have been cancelled for business reasons to expedite the prosecution of the present application. New Claims 84-147 have been added. New Claims 84-147 are within Group I, which has been elected.

Information Disclosure Statement

An information disclosure statement is being filed with this communication. Applicants request that these references be made of reference in this application.

If the Examiner wishes to discuss this case, Applicants encourage the Examiner to call the undersigned at 608-218-6900 at the Examiner's convenience.

Dated: _____

August 17, 2006

Jason R. Bond
Registration No. 45,439

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608/218-6900